Physician profile
Steven J Krozer
NPI 1073060737
$139,237.99
in general payments reported to CMS, 2019-2025
34 companies · $49K in 2025
The $49K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20K · 2022: $25K · 2023: $21K · 2024: $23K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Travel and Lodging: $17K · Consulting Fee: $12K · Food and Beverage: $10K · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,170.00 |
| Travel and Lodging | $16,639.64 |
| Consulting Fee | $11,519.00 |
| Food and Beverage | $10,488.33 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $113,952.74 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Janssen Scientific Affairs, LLC | $9,541.98 | 2022-2025 | Invega, Invega Trinza, Invega Sustenna |
| Abbvie INC. | $4,036.38 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $2,210.31 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $1,235.05 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,103.32 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $958.90 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Alkermes, INC. | $789.74 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Takeda Pharmaceuticals U.S.A., INC. | $729.76 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $661.37 | 2022-2025 | Auvelity, Sunosi |
| Sunovion Pharmaceuticals INC. | $536.46 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $442.38 | 2021-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $432.80 | 2021-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $430.87 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $275.26 | 2021-2025 | Uzedy, Austedo Xr |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $274.71 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $256.88 | 2021-2024 | Nuplazid |
| Bausch Health US, LLC | $229.70 | 2021-2025 | Aplenzin |
| Livanova USA, INC. | $197.71 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Tris Pharma INC | $151.73 | 2022-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $134.47 | 2024 | |
| Almatica Pharma LLC | $131.17 | 2021-2025 | Loreev Xr |
| Biogen, INC. | $104.47 | 2023 | |
| Corium, LLC | $67.30 | 2022-2024 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.51 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $46.11 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $44.82 | 2021 | |
| Eisai INC. | $42.89 | 2021-2022 | |
| Noven Therapeutics, LLC | $40.34 | 2025 | Xelstrym |
| Gilead Sciences, INC. | $32.22 | 2021 | |
| Neos Therapeutics, Lp | $30.89 | 2021-2023 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $30.03 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $12.76 | 2021 | |
| Neuronetics, INC. | $8.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Krozer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.